Pharma Focus Asia

Moderna Collaborates with Generation Bio

Friday, March 24, 2023

Moderna and Generation Bio announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.

Under the terms of the agreement, Moderna advances two immune cell programmes, each of which will use a jointly developed ctLNP to deliver ceDNA. In addition, Moderna will advance two liver programmes, each of which uses a liver-targeted ctLNP developed by Generation Bio to deliver ceDNA.

This collaboration, based on Generation Bio's non-viral genetic medicines platform, will have the potential to target immune cells with diverse nucleic acid cargos and the liver for gene replacement. This partnership broadens the therapeutic pipeline and extend the potential benefits of nucleic acid therapy to more patients.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024